Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: cannabidiol
Trade Name: Epidiolex
Date Designated: 02/27/2014
Orphan Designation: Treatment of Lennox-Gastaut syndrome
Orphan Designation Status: Designated/Approved
GW Research Ltd.
Sovereign House
Histon
Cambridge
United Kingdom

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: cannabidiol
Trade Name: Epidiolex
Marketing Approval Date: 09/28/2018
Approved Labeled Indication: EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.
Exclusivity End Date: 09/28/2025 
Exclusivity Protected Indication* :  EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
2 Generic Name: cannabidiol
Trade Name: EPIDIOLEX
Marketing Approval Date: 07/31/2020
Approved Labeled Indication: treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of age and older.
Exclusivity End Date: 07/31/2027 
Exclusivity Protected Indication* :  treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients between 1 and 2 years of age
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-